SAREPTA THERAPEUTICS, INC.
A biopharmaceutical company.
The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 7 of its records are shown together here.
These two are not added together. An organisation lobbying for itself reports its own spending, and the firms it retains report what they were paid; the rules ask the first to include the second, but filings do not always do so and a filing gives no way to tell. Each is shown as reported.
Reported lobbying by year
Filings
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Report 3rd Quarter 2026
|
TARPLIN, DOWNS & YOUNG, LLC | $90,000 reported |
|
3rd Quarter - Report 3rd Quarter 2026
|
SAREPTA THERAPEUTICS, INC. | $160,000 reported |
|
2nd Quarter - Termination 2nd Quarter 2026
|
MICHAEL BEST STRATEGIES LLC | $50,000 reported |
|
2nd Quarter - Report 2nd Quarter 2026
|
TARPLIN, DOWNS & YOUNG, LLC | $90,000 reported |
|
2nd Quarter - Report 2nd Quarter 2026
|
SAREPTA THERAPEUTICS, INC. | $220,000 reported |
|
1st Quarter - Report 1st Quarter 2026
|
MICHAEL BEST STRATEGIES LLC | $110,000 reported |
|
1st Quarter - Report 1st Quarter 2026
|
SAREPTA THERAPEUTICS, INC. | $270,000 reported |
|
1st Quarter - Report 1st Quarter 2026
|
TARPLIN, DOWNS & YOUNG, LLC | $90,000 reported |
|
4th Quarter - Amendment 4th Quarter 2025
|
TARPLIN, DOWNS & YOUNG, LLC | $90,000 reported |
|
4th Quarter - Amendmentreplaced 4th Quarter 2025
|
TARPLIN, DOWNS & YOUNG, LLC | $90,000 reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| SAREPTA THERAPEUTICS, INC. In-house | 48 | $7,790,000 |
| TARPLIN, DOWNS & YOUNG, LLC | 49 | $3,960,000 |
| FORBES-TATE | 17 | $800,000 |
| MICHAEL BEST STRATEGIES LLC | 5 | $420,000 |
| SQUIRE PATTON BOGGS | 3 | $80,000 |
| WALLER LANSDEN DORTCH & DAVIS LLP | 4 | $75,000 |
| CORNERSTONE GOVERNMENT AFFAIRS, INC. | 4 | $70,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 130 |
| Budget/Appropriations | BUD | 87 |
| Medicare/Medicaid | MMM | 75 |
| Taxation/Internal Revenue Code | TAX | 14 |
| Copyright/Patent/Trademark | CPT | 13 |
| Science/Technology | SCI | 11 |
| Medical/Disease Research/Clinical Labs | MED | 6 |
| Pharmacy | PHA | 4 |
| Trade (domestic/foreign) | TRD | 2 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
| Bill | Congress | Times named |
|---|---|---|
| H.Con.Res. 27 | 114th | 16 |
| S.Con.Res. 11 | 114th | 16 |
| H.R. 1319 | 117th | 15 |
| H.R. 6 | 114th | 14 |
| S. 2543 | 116th | 13 |
| S. 204 | 115th | 13 |
| H.R. 3 | 116th | 12 |
| H.R. 749 | 115th | 12 |
| S. 771 | 115th | 12 |
| S. 469 | 115th | 12 |
| S. 637 | 115th | 12 |
| S. 2030 | 114th | 12 |
| H.R. 2430 | 115th | 11 |
| S. 1137 | 114th | 10 |
| S. 779 | 114th | 10 |
| H.R. 1314 | 114th | 10 |
| H.R. 9 | 114th | 10 |
| H.R. 3921 | 115th | 9 |
| S. 1827 | 115th | 9 |
| S. 456 | 115th | 9 |
| H.R. 1839 | 116th | 8 |
| H.R. 259 | 116th | 8 |
| S. 2742 | 114th | 8 |
| S. 1878 | 114th | 8 |
| S. 2713 | 114th | 8 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.